5-(1-金刚烷基)-4-乙基-2H-1,2,4-三唑-3-硫酮 | 139158-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(1-金刚烷基)-4-乙基-2H-1,2,4-三唑-3-硫酮
• 中文别名: (9S)-3,10-二脱氢-10,11-二氢-6'-甲氧基辛可烷-9-醇乙酸酯
• 英文名称: 3-(adamantan-1-yl)-4-ethyl-1H-1,2,4-triazole-5(4H)-thione
• 英文别名: 3-(1-adamantyl)-4-ethyl-1,2,4-triazoline-5-thione；3H-1,2,4-Triazole-3-thione, 2,4-dihydro-4-ethyl-5-tricyclo(3.3.1.1(sup 3,7))dec-1-yl-；3-(1-adamantyl)-4-ethyl-1H-1,2,4-triazole-5-thione
• CAS: 139158-25-1
• 化学式: C₁₄H₂₁N₃S
• mdl: MFCD25687984
• 分子量: 263.407
• InChiKey: ZVCRUHHERRHVBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(1-金刚烷基)-4-乙基-2H-1,2,4-三唑-3-硫酮 在 sodium hydroxide 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 5.0h， 生成 2-[3-(1-adamantyl)-4-ethyl-5-thioxo-1,2,4-triazolin-1-yl]propionic acid
  参考文献：
  名称：

  Al-Deeb, Omar A.; Al-Omar, Mohamed A.; El-Brollosy, Nasser R., Arzneimittel-Forschung/Drug Research, 2006, vol. 56, # 1, p. 40 - 47

  摘要：

  DOI：
• 作为产物：
  描述：

  金刚烷-1-甲酰肼 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 5-(1-金刚烷基)-4-乙基-2H-1,2,4-三唑-3-硫酮
  参考文献：
  名称：

  El-Emam; Ibrahim, Arzneimittel-Forschung/Drug Research, 1991, vol. 41, # 12, p. 1260 - 1264

  摘要：

  DOI：

文献信息

• Combination therapy for the treatment of obesity
  申请人：——

  公开号：US20040122033A1

  公开（公告）日：2004-06-24

  The present invention relates to compositions comprising an appetite suppressant and/or a metabolic rate enhancer and/or a nutrient absorption inhibitor useful for the treatment of obesity, and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

  本发明涉及一种包含食欲抑制剂和/或代谢率增强剂和/或营养吸收抑制剂的组合物，用于治疗肥胖和与肥胖相关的疾病。本发明还涉及通过给予本发明的组合物来治疗或预防肥胖和与肥胖相关的疾病的方法。本发明还提供了用于执行这些方法的制药组合物、药物和工具包。
• [EN] METHOD OF TREATMENT OR PREVENTION OF OBESITY<br/>[FR] METHODE DE TRAITEMENT OU DE PREVENTION DE L'OBESITE
  申请人：MERCK & CO INC

  公开号：WO2003075660A1

  公开（公告）日：2003-09-18

  The present invention relates to a method of treating or preventing obesity (or suppressing the appetite) in a human patient by antagonizing CB1 receptors and inhibiting the enzyme 11β-HSD1 in an amount that is effective to treat or prevent obesity. Compounds useful in the present invention have an ion channel activity level greater than about 2 µM. Preferably the compound is a dual selective inhibitor, selectively antagonizing CB1 receptors and selectively inhibiting the enzyme 11β-HSD1.

  本发明涉及一种通过拮抗CB1受体并抑制11β-HSD1酶的方法来治疗或预防人类患者的肥胖症（或抑制食欲）。在治疗或预防肥胖症方面，本发明中有用的化合物具有大于约2µM的离子通道活性水平。最好的情况是，该化合物是一种双重选择性抑制剂，选择性地拮抗CB1受体并选择性地抑制11β-HSD1酶。
• Method of treatment or prevention of obesity
  申请人：Fong M Tung

  公开号：US20050171161A1

  公开（公告）日：2005-08-04

  The present invention relates to a method of treating or preventing obesity (or suppressing the appetite) in a human patient by antagonizing CB1 receptors and inhibiting the enzyme 11β-HSD1 in an amount that is effective to treat or prevent obesity. Compounds useful in the present invention have an ion channel activity level greater than about 2 μM. Preferably the compound is a dual selective inhibitor, selectively antagonizing CB1 receptors and selectively inhibiting the enzyme 11β-HSD1

  本发明涉及一种通过拮抗CB1受体和抑制11β-HSD1酶以有效治疗或预防肥胖（或抑制食欲）的方法。本发明中有用的化合物具有大于约2μM的离子通道活性水平。最好的化合物是双重选择性抑制剂，可以选择性地拮抗CB1受体和选择性地抑制酶11β-HSD1。
• 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：Balkovec M. James

  公开号：US20050070720A1

  公开（公告）日：2005-03-31

  Compounds having Formula (I), including pharmaceutically acceptable salts and prodrugs thereof: are selective inhibitors of the 11β-HSD1 enzyme. They inhibit the 11β-HSD1-mediated conversion of cortisone and other 11-keto-glucocorticoids to cortisol and other 11β-hydroxy-glucocorticoids. The 11β-HSD1 inhibitors therefore decrease the amount of cortisol in target tissues, thereby modulating the effects of cortisol. Modulation of cortisol may be effective in controlling non-insulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM or with excess cortisol in the body.

  化合物公式为（I）的化合物，包括其药学上可接受的盐和前药：是11β-HSD1酶的选择性抑制剂。它们抑制11β-HSD1介导的可的松和其他11-酮基-糖皮质激素转化为皮质醇和其他11β-羟基-糖皮质激素的过程。因此，11β-HSD1抑制剂减少了目标组织中皮质醇的含量，从而调节了皮质醇的效应。调节皮质醇可能对控制非胰岛素依赖性糖尿病（NIDDM）、高血糖、肥胖症、胰岛素抵抗、血脂异常、高脂血症、高血压、X综合征和与体内过多皮质醇有关的其他症状有效。
• 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：Merck & Co., Inc.

  公开号：US07329683B2

  公开（公告）日：2008-02-12

  Compounds having Formula (I), including pharmaceutically acceptable salts and prodrugs thereof: are selective inhibitors of the 11β-HSD1 enzyme. They inhibit the 11β-HSD1-mediated conversion of cortisone and other 11-keto-glucocorticoids to cortisol and other 11β-hydroxy-glucocorticoids. The 11β-HSD1 inhibitors therefore decrease the amount of cortisol in target tissues, thereby modulating the effects of cortisol. Modulation of cortisol may be effective in controlling non-insulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM or with excess cortisol in the body

  化合物公式(I)的化合物，包括其药学上可接受的盐和前药：是11β-HSD1酶的选择性抑制剂。它们抑制11β-HSD1介导的可的松和其他11-酮基-糖皮质激素转化为皮质醇和其他11β-羟基-糖皮质激素的过程。因此，11β-HSD1抑制剂减少了目标组织中皮质醇的量，从而调节了皮质醇的作用。调节皮质醇可能对控制非胰岛素依赖性糖尿病（NIDDM）、高血糖、肥胖症、胰岛素抵抗、血脂异常、高脂血症、高血压、X综合症和与体内过量皮质醇相关的其他症状有效。